ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39792474.
- Also identified by DOI 10.1158/1078-0432.CCR-24-3805.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although deemed potentially curative, surgical resection of hepatocellular carcinoma is associated with >70% risk of postoperative relapse. Recurrence is uniquely multifactorial in hepatocellular carcinoma, potentially stemming from metachronous reoccurrence of the original tumor or de novo cancerization. ctDNA may improve personalized risk stratification after resection, a setting where adjuvant immunotherapy has failed to provide survival benefit. See related article by Hu et al., p. 1047.
Medical subject headings
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Circulating Tumor DNA
- Precision Medicine
- Biomarkers, Tumor
- Neoplasm Recurrence, Local